anti-melanoma mab fragments
Various (V09)Various (V09) compound in IO Biotech's portfolio. Mechanism: Diagnostic agent.
- Mechanism
- Diagnostic agent
biotech · Melanoma · Previously untreated, unresectable, or metastatic melanoma · IOBTQ
IO Biotech
IO Biotech drug portfolio — 8 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Ole Maaloesvej 3, Copenhagen, Denmark 2200, DK HQ
2015 Founded
50 Employees
Public company Type
IOBTQ · NYSE Ticker
Company details
- Status
- Public
- HQ
- Ole Maaloesvej 3, Copenhagen, Denmark 2200, DK
- Founded
- 2015
- Employees
- 50
- Programs
- 16
- Drugs
- 8
- Patents
- 21
IO Biotech pipeline
Portfolio lens on 8 drugs and development assets — regulatory status, targets, and deep links to NovaPharmaNews drug profiles.
IO Biotech drug portfolio — 8 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Drug portfolio
-
-
Development asset linked to IO Biotech in public FDA and regional records.
-
Development asset linked to IO Biotech in public FDA and regional records.
-
Development asset linked to IO Biotech in public FDA and regional records.
-
pembrolizumab
Antineoplastic and immunomodulating agents (L01)US regulatory status: approved. Molecular target: Programmed cell death protein 1.
- Target
- Programmed cell death protein 1
- Mechanism
- Programmed cell death protein 1 inhibitor
-
Development asset linked to IO Biotech in public FDA and regional records.
-
Development asset linked to IO Biotech in public FDA and regional records. Mechanism: Estrogen receptor alpha modulator.
- Mechanism
- Estrogen receptor alpha modulator
-
Development asset linked to IO Biotech in public FDA and regional records.